Genetic Sucrase-Isomaltase Deficiency Clinical Trial
— GSID-EOfficial title:
A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
| Verified date | September 2017 |
| Source | QOL Medical, LLC |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
S09A is a Phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel study examining the efficacy and safety of a Sucraid (sacrosidase) Oral Solution in comparison to a placebo in 150-200 subjects with chronic diarrhea possibly attributable to sucrase deficiency.
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | December 2017 |
| Est. primary completion date | December 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 16 Years and older |
| Eligibility |
Inclusion Criteria: 1. Subject is 16 years of age or older. 2. Subject is male or female. Women of childbearing potential must be willing to use one of the following contraception methods (for at least 10 days prior to start of study drug and for 10 to 14 days after last dose of study drug): Oral contraceptive, Injectable progestogen, Implants of levonorgestrel, Estrogenic vaginal ring, Percutaneous contraceptive patches, Intrauterine device, Sterile male partner, Double-barrier method of contraception Women of non-child bearing potential include females regardless of age with functioning ovaries and who have a current tubal ligation (Hatcher, 2004), bilateral oophorectomy, or total hysterectomy, or post-menopausal females. Note: Post-menopausal is defined as 1 year without menses with an appropriate clinical profile (e.g., age appropriate, >45 years, in the absence of hormone replacement therapy). 3. Subject has a minimum of 3 months of self-reported diarrhea (BSFS scores = 5 on at least 3 days per week and =1 stool per day) 4. Subject has a value in the SHMBT of at least 20 ppm for hydrogen, or 12 ppm for methane or 15 ppm above a previous breath sample for the combination of both gases. 5. Subject reports that he/she experienced soft stools or diarrhea within the last 24 hours when contacted by the site 24 hours after completing the SHMBT. 6. Subject is able to read, speak, and verbally understand the English language. 7. Subject is located in the United States. 8. Subject has access to the Internet on a daily basis. 9. Subject has access to an acceptable Apple iPhone/iPad/iTouch or Android smartphone/tablet. The sponsor may choose to provide a smartphone in unusual cases (please contact sponsor to request loaner device when applicable) Exclusion Criteria: 1. Subject has recent history of functional or chronic constipation. 2. Subject has known history of ulcerative colitis, Crohn's disease, or Celiac disease. 3. Subject has known hypersensitivity to papain, glycerol, or yeast. 4. Subject has received bovine serum in the last year. 5. Subject has previous history of Sucraid use. 6. Subject has taken any prebiotic or probiotic within 5 days prior to Visit 2 and does not agree to refrain from taking them during the study. 7. Subject is female and is pregnant, breastfeeding, or planning to become pregnant during the study. 8. Subject has known uncontrolled systemic disease. 9. Subject has prior diagnosis of Type 1 or Type 2 diabetes. 10. Subject has history of bowel resection. 11. Subject is undergoing chemotherapy for the treatment of cancer. 12. Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial. 13. Subject has used an investigational device or investigational drug within 30 days prior to Visit 1. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| QOL Medical, LLC |
Arthur AB. Intestinal disaccharidase deficiency in children with coeliac disease. Arch Dis Child. 1966 Oct;41(219):519-24. — View Citation
Bayless TM, Christopher NL. Disaccharidase deficiency. Am J Clin Nutr. 1969 Feb;22(2):181-90. Review. — View Citation
Chumpitazi BP, Robayo-Torres CC, Tsai CM, Opekun AR, Baker SS, Nichols BL, Gilger MA, Su1110 Yield of prospective disaccharidase testing in children with recurrent abdominal pain. Gastroenterology. May 2013;144(5):S-401-S402.
Cross HS, Quaroni A. Inhibition of sucrose-isomaltase expression by EGF in the human colon adenocarcinoma cells Caco-2. Am J Physiol. 1991 Dec;261(6 Pt 1):C1173-83. — View Citation
Czernichow B, Simon-Assmann P, Kedinger M, Arnold C, Parache M, Marescaux J, Zweibaum A, Haffen K. Sucrase-isomaltase expression and enterocytic ultrastructure of human colorectal tumors. Int J Cancer. 1989 Aug 15;44(2):238-44. — View Citation
DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994 Jul 15-30;13(13-14):1341-52; discussion 1353-6. — View Citation
El-Chammas K, Williams S, Miranda A. Su1254 Lactase and sucrase deficiencies in pediatric subjects with chronic abdominal pain. Gastroenterology. May 2014;146(5):S-415-S416.
Gupta SK, Chong SK, Fitzgerald JF. Disaccharidase activities in children: normal values and comparison based on symptoms and histologic changes. J Pediatr Gastroenterol Nutr. 1999 Mar;28(3):246-51. — View Citation
Hatcher RA, Trussell J, Stewart F, Nelson AL, Cates W, Guest F, Kowal DD, editors. Contraceptive Technology. New York: Ardent Media, 2004:226.
Heitlinger LA, Rossi TM, Lee PC, Lebenthal E. Human intestinal disaccharidase activities: correlations with age, biopsy technique, and degree of villus atrophy. J Pediatr Gastroenterol Nutr. 1991 Feb;12(2):204-8. — View Citation
Hyams JS, Batrus CL, Grand RJ, Sallan SE. Cancer chemotherapy-induced lactose malabsorption in children. Cancer. 1982 Feb 15;49(4):646-50. — View Citation
Kerry KR, & Townley, R. R. Genetic aspects of intestinal sucrase-isomaltase deficiency. Australian Paediatric Journal. 1965;1:223.
Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics. 1999 Dec;55(4):1286-90. — View Citation
Mones RL, Yankah A, Duelfer D, Bustami R, Mercer G. Disaccharidase deficiency in pediatric patients with celiac disease and intact villi. Scand J Gastroenterol. 2011 Dec;46(12):1429-34. doi: 10.3109/00365521.2011.619276. Epub 2011 Sep 22. — View Citation
Murray IA, Smith JA, Coupland K, Ansell ID, Long RG. Intestinal disaccharidase deficiency without villous atrophy may represent early celiac disease. Scand J Gastroenterol. 2001 Feb;36(2):163-8. — View Citation
Nichols BL Jr, Adams B, Roach CM, Ma CX, Baker SS. Frequency of sucrase deficiency in mucosal biopsies. J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S28-30. doi: 10.1097/01.mpg.0000421405.42386.64. — View Citation
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979 Sep;35(3):549-56. — View Citation
Osterlund P, Ruotsalainen T, Peuhkuri K, Korpela R, Ollus A, Ikonen M, Joensuu H, Elomaa I. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol. 2004 Aug;2(8):696-703. — View Citation
Quezada-Calvillo R, Sim L, Ao Z, Hamaker BR, Quaroni A, Brayer GD, Sterchi EE, Robayo-Torres CC, Rose DR, Nichols BL. Luminal starch substrate "brake" on maltase-glucoamylase activity is located within the glucoamylase subunit. J Nutr. 2008 Apr;138(4):685-92. — View Citation
Reed, JF. (2006) AB/BA Crossover Trials - Binary Outcome. J Modern Applied Stat Methods 5 (2): 452-457.
Treem WR, Ahsan N, Sullivan B, Rossi T, Holmes R, Fitzgerald J, Proujansky R, Hyams J. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency. Gastroenterology. 1993 Oct;105(4):1061-8. — View Citation
Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999 Feb;28(2):137-42. — View Citation
Treem WR. Clinical aspects and treatment of congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S7-13. doi: 10.1097/01.mpg.0000421401.57633.90. — View Citation
Treem WR. Congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1995 Jul;21(1):1-14. Review. — View Citation
Uhrich S, Wu Z, Huang JY, Scott CR. Four mutations in the SI gene are responsible for the majority of clinical symptoms of CSID. J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S34-5. doi: 10.1097/01.mpg.0000421408.65257.b5. — View Citation
Wiecek S, Wos H, Radziewicz Winnicki I, Komraus M, Grzybowska Chlebowczyk U. Disaccharidase activity in children with inflammatory bowel disease. Turk J Gastroenterol. 2014 Apr;25(2):185-91. doi: 10.5152/tjg.2014.3994. — View Citation
* Note: There are 26 references in all — Click here to view all references
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Response to Sucraid and placebo in a parallel group study based on improvement in daily stool consistency, as assessed by the BSFS using SHMBT | Response to Sucraid and placebo based on improvement in daily stool consistency, as assessed by the Bristol Stool Form Scale (BSFS) over a 1-week treatment period in subjects with chronic diarrhea and sucrase deficiency using a sucrose hydrogen methane breath test (SHMBT). | Up to 2 years | |
| Secondary | Effects of Sucraid and placebo on daily assessments of Bristol Stool Form Scale | Up to 2 years | ||
| Secondary | Effects of Sucraid and placebo on daily stool frequency | Up to 2 years | ||
| Secondary | Effects of Sucraid and placebo on daily abdominal pain | Up to 2 years | ||
| Secondary | Effects of Sucraid and placebo on daily bloating severity | Up to 2 years | ||
| Secondary | The relationship between the severity of sucrase deficiency, quantified by a SHMBT | Up to 2 years | ||
| Secondary | The mean improvement in the BSFS for each treatment group. | Up to 2 years | ||
| Secondary | Overall frequency of the 4 most common sucrase-isomaltase deficiency genetic variants | Overall frequency of the 4 most common sucrase-isomaltase deficiency genetic variants in comparison to the frequency in public proxy databases of broad populations. | Up to 2 years | |
| Secondary | The number of less common sucrase-isomaltase polymorphisms in this study population. | Up to 2 years | ||
| Secondary | The allele frequency of the most common sucrase-isomaltase genetic variants in subjects with chronic diarrhea attributable to sucrase deficiency compared to the allele frequency in other databases | Assess the allele frequency of the 38 most common sucrase-isomaltase genetic variants in subjects with chronic diarrhea attributable to sucrase deficiency compared to the allele frequency of sucrase-isomaltase genetic variants in the Exome Variant Server, the ExAC server, and other public proxy and private genetic databases. | Up to 2 years |